샘플 요청 목록

 카트 문의
시장보고서
상품코드
1559472

세계 위암 진단 : 시장 인사이트, 경쟁 환경, 시장 예측(-2030년)

Gastric Cancer Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2030
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

위암 진단 시장 규모는 2024-2030년의 예측 기간 동안 CAGR 7.31%로 성장할 것으로 예측됩니다.

위암 진단 수요는 주로 세계에서 위암 환자가 증가하고 있는 것이 배경에 있습니다. 헬리코박터 파일로리와 위장염과 같은 위 감염 증가와 GERD 및 기타 위 관련 질환의 유병률 증가가 시장 성장에 기여합니다. 또한 위암의 발병으로 이어지는 비만과 흡연 습관 증가도 예측 기간 동안 시장 성장을 가속하는 주요 요인의 일부입니다.

세계보건기구(WHO)가 국제암연구기관(IARC)과 공동으로 실시한 조사(2022년)에 따르면 위암의 신규 환자수는 2020년 109만명에서 2040년 181만명으로 증가하고 신규 환자 수의 75%가 아시아에서 진단될 것으로 예상됩니다. 이 예측은 신규 사례가 약 63% 증가하고 사망률이 66% 증가함을 보여줍니다. 같은 출처에 따르면 2020년에는 소화기 암이 세계 암 환자 4명 중 1명을 차지할 것으로 추산되고 있습니다.

IARC의 2024년 데이터에 따르면 유럽 위암의 총 환자수는 2022년 13만 6,000명에서 2045년 17만명으로 증가할 것으로 예상됩니다.

NCI(미국립암 연구소)가 2024년 1월에 발표한 연구에 따르면 헬리코박터 파일로리(필로리균)는 위암과 관련된 유일한 세균성 발암물질인 것으로 확인되었습니다. 2020년에는 필로리균은 특히 위종양이라는 형태로 85만건의 새로운 암 증례의 원인이 되었습니다. 이러한 점에서 필로리균 감염의 유병률 증가가 위암 진단 시장의 성장을 견인하고 있습니다.

또한 WHO는 2024년 18세 이상의 성인 25억 명이 과체중이며, 그 중 8억 9,000만 명이 비만이라고 보고했습니다. 체중 과다는 혈액 중 인슐린과 관련 호르몬의 농도를 높이고 위암 발병의 위험을 높입니다. 따라서 비만자 증가도 위암 진단 시장의 확대에 기여하고 있습니다.

이 보고서는 세계 위암 진단 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법 규제 환경, 시장 규모 추이 및 예측, 각종 구분, 지역/주요 국가별 상세 분석, 경쟁 정세, 주요 기업 프로파일 등을 정리했습니다.

목차

제1장 위암 진단 시장 : 소개

제2장 위암 진단 시장 : 주요 요약

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 위암 진단 시장 : 주요 요인 분석

  • 시장 성장 촉진요인
    • 세계 위암의 증례가 증가
    • 위식도 역류증(GERD) 및 기타 위 관련 질환의 이환율 증가
    • 필로리균이나 위장염 등 위의 감염증 증가
  • 시장 성장 억제요인과 과제
    • 위암 검진에서의 위음성의 가능성
    • 위암을 조기 발견하기 위한 진단 도구의 비효율성
  • 시장 기회
    • 조기 진단을 위한 특이적 바이오마커의 발견
    • 위암의 조기 진단에서 AI와 로봇의 통합

제6장 위암 진단 시장 : Porter's Five Forces 분석

제7장 위암 진단 시장 : 시장 평가

  • 제품 유형별
    • 기기
    • 시약 및 키트
  • 검사 유형별
    • 영상 검사
    • 임상 검사
  • 최종 사용자별
    • 병원
    • 진단 실험실
    • 학술 및 연구기관
    • 진단센터
    • 기타
  • 지역별
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제8장 위암 진단 시장 : 기업 및 제품 프로파일

  • Abbott
  • BD
  • Bio-Rad Laboratories, Inc.
  • F. Hoffmann-La Roche Ltd
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Pillar Biosciences Inc.
  • Hologic, Inc.
  • CD Genomics
  • Natera, Inc.
  • Biodesix
  • Illumina, Inc.
  • Quest Diagnostics
  • Agilent Technologies, Inc.
  • FUJIFILM Holdings Corporation
  • NeoGenomics Laboratories
  • Guardant Health
  • Myriad Genetics, Inc.
  • Invitae Corporation
  • Danaher

제9장 KOL의 견해

제10장 프로젝트 접근

제11장 DelveInsight 정보

제12장 면책사항 및 문의

JHS 24.10.02

Gastric Cancer Diagnostics Market by Product Type (Instruments, Reagents & Kits), Test Type (Imaging Test [Upper Endoscopy, Barium Swallow/X-Rays, CT Scan, Laparoscopy, MRI, Stomach Ultrasound, and Others], Laboratory Test [Biopsy, Blood Test, and Others]), End-Users (Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the growing prevalence of gastric cancer, increasing cases of stomach infection such as h. pylori and gastroenteritis, among others

The gastric cancer diagnostics market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030. The demand for gastric cancer diagnostics is primarily being driven by the rising cases of gastric cancer across the globe. The growing prevalence of GERD and other stomach-related conditions coupled with increasing cases of stomach infections such as H. Pylori and gastroenteritis is contributing to the growth of the market. Further, the rising obesity and smoking habits leading to the development of stomach cancer are some of the key factors that are driving the market growth of the gastric cancer diagnostics market during the forecast period from 2024 to 2030.

Gastric Cancer Diagnostics Market Dynamics:

According to the study conducted by the World Health Organization (WHO) in collaboration with the International Agency for Research on Cancer (IARC) (2022), WHO projects gastric cancer incidence to increase from 1.09 million new cases in 2020 to 1.81 million by 2040, with 75 percent of new cases diagnosed in Asia. This trajectory indicates an upsurge of around 63% in new cases and a corresponding 66% rise in mortality rates, due to a lack of diagnosis and treatment facilities in poor countries. According to the same source in 2020, Gastrointestinal (GI) cancers accounted for 1 in 4 cancer cases in the world.

According to the International Agency for Research on Cancer (IARC) (2024), the total number of stomach cancer cases was 136 thousand in 2022 and this number is expected to reach 170 thousand by 2045 in Europe.

A study published by the National Cancer Institute in January 2024 highlighted that Helicobacter pylori (H. pylori) is the only confirmed bacterial carcinogen linked to gastric cancer. In 2020, H. pylori was responsible for 850,000 new cancer cases, particularly in the form of gastric tumors. Consequently, the increasing prevalence of H. pylori infections is driving the growth of the gastric cancer diagnostics market.

Additionally, the World Health Organization (WHO) reported in 2024 that 2.5 billion adults aged 18 years or older were overweight in 2022, with 890 million of them living with obesity. Excess body weight leads to higher levels of insulin and related hormones in the blood, which in turn increases the risk of developing stomach cancer. Therefore, the rising number of obese individuals is also contributing to the expansion of the gastric cancer diagnostics market.

However, the chances of false-negative results in gastric cancer screening and, the inefficiency of diagnostic tools to detect gastric cancer at an early stage, among others are some of the key constraints that may hinder the growth of the gastric cancer diagnostics market.

Gastric Cancer Diagnostics Market Segment Analysis:

Gastric Cancer Diagnostics Market By Product Type (Instruments, Reagents & Kits), Test Type (Imaging Test [Upper Endoscopy, Barium Swallow/X-Rays, CT Scan, Laparoscopy, MRI, Stomach Ultrasound, and Others], Laboratory Test [Biopsy, Blood Test, and Others]), End-Users (Hospitals, Diagnostic Laboratories, Academic & Research Institutes, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the gastric cancer diagnostics market, the reagents & kits category was estimated to generate a significant revenue share in the gastric cancer diagnostics market in 2023. This can be attributed to the growing use of reagents and kits in cancer diagnosis due to the rising prevalence of gastric cancer across the globe. The growing awareness about early cancer diagnosis is a major factor contributing to the growth of the segment. In gastric biopsy, essential reagents encompass fixatives like formalin for tissue preservation, staining agents such as hematoxylin and eosin for microscopic analysis, and immunohistochemical stains aiding in the identification of cancer cell markers. Additionally, common markers utilized for gastric cancer detection include Carcinoembryonic antigen (CEA) and Carbohydrate antigen 19-9 (CA 19-9), with mucin-staining reagents being frequently employed in diagnostic procedures. These reagents are widely used in procedures for early gastric cancer diagnosis.

In October 2021, Boditech Med Inc. launched the ichroma Tumor triple-M diagnostic kit. This product is specifically developed for the early detection of gastric cancer. It contains Carcinoembryonic Antigen (CEA), a vital component utilized in the identification of stomach cancer. CEA serves as a pivotal tool in cancer screening, monitoring, prognostics, and predictive analysis both pre and post-surgery.

Further, the utilization of reagents and kits for the examination and detection of proteins and genes in gastric cancer diagnosis, particularly for early detection and facilitating appropriate treatment, significantly fuels the expansion of this segment. Therefore, the growing use of reagents and kits is expected to contribute to the growth of the segment, thereby driving the growth of the overall gastric cancer diagnostics market during the forecast period.

North America Is Expected To Dominate The Overall Gastric Cancer Diagnostics Market:

North America was estimated to account for the largest market share in the gastric cancer diagnostics market in 2023. This is due to the rising prevalence of gastric cancer and other stomach diseases contributing to the growth of gastric cancer. Additionally, the rising geriatric population and technological advancement in early cancer diagnosis are the major factors contributing to the growth of the gastric cancer diagnostics market in the region.

According to data published by the American Cancer Society in January 2024, approximately 26,890 new cases of stomach cancer are projected to occur in the United States in 2024. Of these, men are estimated to account for 16,160 cases, while women will account for 10,730 cases. Stomach cancer represents about 1.5% of all new cancer diagnoses in the country each year. This type of cancer predominantly affects older individuals, with the average age of diagnosis being 68 years, and around 60% of cases occurring in those aged 65 and older. The lifetime risk of developing stomach cancer is significantly higher in men, with approximately 1 in 101 men and 1 in 155 women facing this risk.

The Population Reference Bureau (2024) forecasts a substantial increase in the demographic of Americans aged 65 and above, from 58 million in 2022 to 82 million by 2050, representing a 47% surge. The proportion of the total population in this age group is expected to rise from 17% to 23%. Gastric cancer is more prevalent among older individuals due to several aging-related risk factors such as stomach infections and gastroesophageal reflux disease (GERD). Consequently, the growing geriatric population is expected to drive the expansion of the gastric cancer diagnostics market in the region.

In March 2024, Ibex Medical Analytics introduced Galen, an AI-powered cancer diagnostic platform. Galen provides accurate diagnoses, reduces manual operations, and is utilized for diagnosing gastric cancer, H. pylori, and other gastric lesions such as adenoma and low-grade dysplasia. Therefore, increasing R&D activities by key players to develop advanced diagnostic solutions is anticipated to foster growth in the North American gastric cancer diagnostics market.

Gastric Cancer Diagnostics Market Key Players:

Some of the key market players operating in the gastric cancer diagnostics market include Abbott, BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Pillar Biosciences Inc., Hologic, Inc., CD Genomics, Natera, Inc., Biodesix, Illumina, Inc., Quest Diagnostics, Agilent Technologies, Inc., FUJIFILM Holdings Corporation, NeoGenomics Laboratories, Guardant Health, Myriad Genetics, Inc., Invitae Corporation, Danaher, and others.

Recent Developmental Activities In The Gastric Cancer Diagnostics Market:

  • In March 2024, AI Medical Service Inc. announced that it had launched gastroAI-model G, an AI-based endoscopic diagnostic support device that operates within the stomach. The diagnostic device operates by scanning for potential lesions, utilizing images derived from the video processor of the endoscopy system. Upon determining that a lesion appears suspicious for early gastric cancer and requires additional evaluation, the program notifies the physician and offers diagnostic support by presenting a highlighted area within the endoscopic display.
  • In November 2023, Dedalus Group in collaboration with Ibex Medical Analytics, announced the launch of a fully integrated AI-powered digital pathology solution for gastric cancer diagnosis.
  • In August 2023, Mirxes Pte Ltd, announced today that its flagship product GASTROClear, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). It is a molecular blood test for the early detection of gastric cancer that helps to cure cancer with affordable treatment.

Key Takeaways From The Gastric Cancer Diagnostics Market Report Study

  • Market size analysis for current Gastric Cancer Diagnostics Market size (2023), and market forecast for 6 years (2024 to 2030)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
  • Key companies dominating the Gastric Cancer Diagnostics market.
  • Various opportunities available for the other competitors in the Gastric Cancer Diagnostics Market space.
  • What are the top-performing segments in 2023? How these segments will perform in 2030?
  • Which are the top-performing regions and countries in the current Gastric Cancer Diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Gastric Cancer Diagnostics market growth in the coming future?

Target Audience Who Can Be Benefited From This Gastric Cancer Diagnostics Market Report Study

  • Gastric Cancer Diagnostics product providers
  • Research organizations and consulting companies
  • Gastric Cancer Diagnostics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and Traders dealing in Gastric Cancer Diagnostics
  • Various end-users who want to know more about the Gastric Cancer Diagnostics Market and the latest technological developments in the Gastric Cancer Diagnostics Market.

Frequently Asked Questions For The Gastric Cancer Diagnostics Market:

1. What are Gastric Cancer Diagnostics?

Gastric cancer diagnostics refers to the set of procedures and technologies utilized to identify and assess the presence of gastric (stomach) cancer in individuals suspected of harboring the disease. These methods encompass a spectrum of diagnostic tools, including imaging modalities, laboratory assays, endoscopic evaluations, and histopathological examinations of tissue samples obtained via biopsies.

2. What is the market for Gastric Cancer Diagnostics?

The gastric cancer diagnostics market is estimated to grow at a CAGR of 7.31% during the forecast period from 2024 to 2030.

3. What are the drivers for the Gastric Cancer Diagnostics market?

The demand for gastric cancer diagnostics is primarily being driven by the rising cases of gastric cancer across the globe. The growing prevalence of GERD and other stomach-related conditions coupled with increasing cases of stomach infections such as H. Pylori and gastroenteritis is contributing to the growth of the market. Further, the rising obesity and smoking habits leading to the development of stomach cancer are some of the key factors that are driving the market growth of the gastric cancer diagnostics market during the forecast period from 2024 to 2030.

4. Who are the key players operating in the Gastric Cancer Diagnostics market?

Some of the key market players operating in the gastric cancer diagnostics market include Abbott, BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Pillar Biosciences Inc., Hologic, Inc., CD Genomics, Natera, Inc., Biodesix, Illumina, Inc., Quest Diagnostics, Agilent Technologies, Inc., FUJIFILM Holdings Corporation, NeoGenomics Laboratories, Guardant Health, Myriad Genetics, Inc., Invitae Corporation, Danaher, and others.

5. Which region has the highest share in the Gastric Cancer Diagnostics market?

North America was estimated to account for the largest market share in the gastric cancer diagnostics market in 2023. This is due to the rising prevalence of gastric cancer and other stomach diseases contributing to the growth of gastric cancer. Additionally, the rising geriatric population and technological advancement in early cancer diagnosis are the major factors contributing to the growth of the gastric cancer diagnostics market in the region.

Table of Contents

1. Gastric Cancer Diagnostics Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Gastric Cancer Diagnostics Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Gastric Cancer Diagnostics Market Key Factors Analysis

  • 5.1. Gastric Cancer Diagnostics Market Drivers
    • 5.1.1. The rising cases of gastric cancer across the globe
    • 5.1.2. Growing prevalence of GERD and other stomach-related conditions
    • 5.1.3. Increasing cases of stomach infections such as H. Pylori and gastroenteritis
  • 5.2. Gastric Cancer Diagnostics Market Restraints and Challenges
    • 5.2.1. Chances of false negative results in gastric cancer screening
    • 5.2.2. The inefficiency of diagnostic tools to detect gastric cancer at an early stage
  • 5.3. Gastric Cancer Diagnostics Market Opportunity
    • 5.3.1. Discovery of specific biomarkers for early diagnosis
    • 5.3.2. Integration of AI and robotics in early gastric cancer diagnostics

6. Gastric Cancer Diagnostics Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Gastric Cancer Diagnostics Market Assessment

  • 7.1. By Product Type
    • 7.1.1. Instruments
    • 7.1.2. Reagents & Kits
  • 7.2. By Test Type
    • 7.2.1. Imaging Test
      • 7.2.1.1. Upper Endoscopy
      • 7.2.1.2. Barium Swallow/X-Rays
      • 7.2.1.3. CT Scan
      • 7.2.1.4. Laparoscopy
      • 7.2.1.5. MRI
      • 7.2.1.6. Stomach Ultrasound
      • 7.2.1.7. Others
    • 7.2.2. Laboratory Test
      • 7.2.2.1. Biopsy
      • 7.2.2.2. Blood Test
      • 7.2.2.3. Others
  • 7.3. By End-User
    • 7.3.1. Hospitals
    • 7.3.2. Diagnostic Laboratories
    • 7.3.3. Academic & Research Institutes
    • 7.3.4. Diagnostic Centers
    • 7.3.5. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.1.2. Canada Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.1.3. Mexico Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.2. Europe
      • 7.4.2.1. France Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.2.2. Germany Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.2.3. United Kingdom Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.2.4. Italy Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.2.5. Spain Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.2.6. Rest of Europe Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.3.2. Japan Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.3.3. India Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.3.4. Australia Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.3.5. South Korea Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.3.6. Rest of Asia-Pacific Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.4.2. Africa Gastric Cancer Diagnostics Market Size in USD million (2021-2030)
      • 7.4.4.3. South America Gastric Cancer Diagnostics Market Size In USD Million (2021-2030)

8. Gastric Cancer Diagnostics Market Company and Product Profiles

  • 8.1. Abbott
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. BD
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Bio-Rad Laboratories, Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. F. Hoffmann-La Roche Ltd
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. Siemens Healthineers AG
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Thermo Fisher Scientific Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Pillar Biosciences Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Hologic, Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. CD Genomics
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Natera, Inc.
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Biodesix
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Illumina, Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Quest Diagnostics
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Agilent Technologies, Inc.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. FUJIFILM Holdings Corporation
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. NeoGenomics Laboratories
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Guardant Health
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Myriad Genetics, Inc.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Invitae Corporation
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. Danaher
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제